Relationship Between and Mutations and MRNA Expression in Breast and Ovarian Cancer Predisposition
Overview
Authors
Affiliations
The aetiology of breast and ovarian cancer (BC/OC) is multi-factorial. At present, the involvement of base excision repair (BER) glycosylases (MUTYH and OGG1) in BC/OC predisposition is controversial. The present study investigated whether germline mutation status and mRNA expression of two BER genes, and , were correlated with in 59 patients with BC/OC and 50 matched population controls. In addition, to evaluate the relationship between , and , their possible mutual modulation and correlation among mutational spectrum, gene expression and demographic characteristics were evaluated. The results identified 18 and variants, of which 4 were novel (2 and 2 ) in 44 of the 59 patients. In addition, two pathogenic mutations were identified: p.Arg46Gln, detected in a patient with BC and a family history of cancer, and p.Val234Gly in a patient with OC, also with a family history of cancer. A significant reduced transcript expression in was observed P=0.033) in cases, and in association with the presence of rare variants in the same gene (P=0.030). A significant correlation in the expression of the two BER genes was observed in cases (P=0.004), whereas OGG1 and BRCA1 was significantly correlated in cases (P=0.001) compared with controls (P=0.010). The results of the present study indicated that the relationship among mutational spectrum, gene expression and demographic characteristics may improve the genetic diagnosis and primary prevention of at-risk individuals belonging to families with reduced mRNA expression, regardless of mutation presence.
Catalano T, Selvaggi F, Cotellese R, Aceto G Cancers (Basel). 2025; 17(5).
PMID: 40075600 PMC: 11899472. DOI: 10.3390/cancers17050752.
Soltani Irdmusa N, Fakhar H, Heshmati M, Akbari M, Rahimi S Breast J. 2025; 2024:3461694.
PMID: 39742378 PMC: 11333139. DOI: 10.1155/2024/3461694.
Moscatello C, Di Marcantonio M, Savino L, DAmico E, Spacco G, Simeone P Cells. 2022; 11(5).
PMID: 35269445 PMC: 8909339. DOI: 10.3390/cells11050822.
Vietri M, DElia G, Caliendo G, Albanese L, Signoriello G, Napoli C Genes (Basel). 2022; 13(2).
PMID: 35205366 PMC: 8872383. DOI: 10.3390/genes13020321.
Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer.
Franchet C, Hoffmann J, Dalenc F Cancers (Basel). 2021; 13(16).
PMID: 34439286 PMC: 8392832. DOI: 10.3390/cancers13164132.